More info that the New York Times left out of its story on Fred Goodwin:
The Times writes:
Here are the facts:
Goodwin consistently studied the effects of lithium a drug that lost it's patent nearly a half century ago and continues to lecture about it's benefits as a front line treatment for manic depression.
Read More
Goodwin also pioneered the use of light therapy to treat season affect disorder.
Meanwhile the Grassley witch hunt continues apace, now "investigating" Goodwin's private consulting business for promoting "off-label" use of lithium. Translation: Publishing an article in JAMA comparing the effect of lithium in reducing suicide among manic depressive patients to marketed products - in partnership with managed care plans and other research organizations -- is now a reason to investigate. And of course just being investigated by Grassley is a crime because taking money from any drug company for any reason at any time makes all of one's research suspect and you a criminal.
Got that?
I can hear the hatchets being sharpened. Shannon Brownlee and Jeanne Lenzer must not be far behind.
The Times writes:
"He defended the views he expressed in many of his radio programs and said that, because he consults for so many drug makers at once, he has no particular bias."
“These companies compete with each other and cancel each other out,” he said. This view is dismissed by industry critics, who say that experts who consult widely for drug makers tend to minimize the value of non-drug or older drug treatments."Here are the facts:
Goodwin consistently studied the effects of lithium a drug that lost it's patent nearly a half century ago and continues to lecture about it's benefits as a front line treatment for manic depression.
Read More
Goodwin also pioneered the use of light therapy to treat season affect disorder.
Meanwhile the Grassley witch hunt continues apace, now "investigating" Goodwin's private consulting business for promoting "off-label" use of lithium. Translation: Publishing an article in JAMA comparing the effect of lithium in reducing suicide among manic depressive patients to marketed products - in partnership with managed care plans and other research organizations -- is now a reason to investigate. And of course just being investigated by Grassley is a crime because taking money from any drug company for any reason at any time makes all of one's research suspect and you a criminal.
Got that?
I can hear the hatchets being sharpened. Shannon Brownlee and Jeanne Lenzer must not be far behind.
